FGF21

Mechanism

A liver-produced hormone triggered by fasting, ketosis, and metabolic stress. It improves insulin sensitivity, promotes fat burning, and may even reduce your preference for sweets. Mice engineered to overproduce FGF21 live about 40% longer. Pharmaceutical analogs are being developed for fatty liver disease (NASH). FGF21 is essentially what makes fasting and keto diets metabolically beneficial.

Effects

## FGF21 — System-by-System Effects ### Metabolic System (Primary) - **Metabolic hormone**: FGF21 (Fibroblast Growth Factor 21) is a hepatokine and adipokine that regulates glucose and lipid metabolism. It is sometimes called a "metabolic master regulator." [Tier 1] - **Insulin sensitization**: FGF21 improves insulin sensitivity in liver, adipose, and skeletal muscle. It acts independently of insulin to promote glucose uptake. [Tier 1 — preclinical, Tier 2 — human data] - **Lipid metabolism**: Reduces circulating triglycerides, improves LDL particle profile, and enhances fatty acid oxidation. [Tier 1 — preclinical] - **Weight management**: FGF21 promotes weight loss primarily through increased energy expenditure and reduced sweet/alcohol preference. Unlike GLP-1 agonists, it does not primarily work through appetite suppression. [Tier 2] - **Brown fat activation**: Stimulates thermogenesis in brown and beige adipose tissue, increasing energy expenditure. [Tier 1 — preclinical] - **Sugar and alcohol preference**: FGF21 reduces preference for sweet foods and alcohol. The FGF21 gene variant rs838133 is associated with sweet preference in human GWAS studies. [Tier 1 for genetics, Tier 2 for therapeutic relevance] ### Hepatic System - **Liver fat reduction**: FGF21 analogs reduce hepatic steatosis (fatty liver) in human trials. This is one of the most clinically advanced applications. [Tier 1 — Phase 2 clinical trial data] - **Hepatoprotection**: Reduces liver inflammation and fibrosis markers. Relevant for NAFLD/NASH, which affects 25%+ of the global population. [Tier 2] ### Cardiovascular System - **Cardioprotection**: FGF21 reduces cardiac hypertrophy and improves cardiac function in preclinical models. [Tier 2] - **Vascular protection**: Improves endothelial function and reduces atherosclerosis in animal models. [Tier 2] - **Lipid improvements**: Clinical trials show significant triglyceride reduction and improved lipid profiles. [Tier 1 — clinical trial data] ### Longevity/Aging - **Longevity signal**: FGF21 overexpression extends lifespan by ~40% in mice (Zhang et al., 2012, eLife). This is one of the most dramatic longevity effects of any single gene manipulation. [Tier 1 — well-replicated animal data] - **Caloric restriction mimetic**: FGF21 is induced by fasting, protein restriction, and ketogenic diets. It may mediate some of the metabolic benefits of these interventions. [Tier 1] - **Aging biomarker**: FGF21 levels increase with age and metabolic dysfunction. Like GDF-15, elevated FGF21 may represent both a protective response and a marker of stress. [Tier 2] ### Neurological System - **Neuroprotection**: Emerging evidence for FGF21 crossing the blood-brain barrier and protecting neurons. [Tier 2] - **Alcohol preference reduction**: FGF21's effect on reducing alcohol intake is being explored for addiction medicine applications. [Tier 2]

Practitioner Guide

## FGF21 — Practitioner Guide ### Clinical Profile FGF21 is an endocrine hormone primarily produced by the liver in response to fasting, protein restriction, and metabolic stress. It coordinates metabolic adaptations across multiple tissues. FGF21 analogs are in clinical development for NASH and metabolic disease. ### Pharmaceutical FGF21 Analogs (Clinical Development) - **Pegbelfermin (BMS)**: Pegylated FGF21 analog. Phase 2 data showed reduction in liver fat and improved metabolic markers in NASH patients. Development was discontinued for commercial reasons. - **Efruxifermin (Akero Therapeutics)**: Fc-FGF21 fusion protein. Ongoing Phase 2b/3 trials for NASH. Showed dramatic liver fat reduction (up to 70%) and fibrosis improvement. One of the most exciting NASH therapies in development. [Tier 1 — Phase 2 data] - **Others**: Multiple pharmaceutical companies pursuing FGF21 pathway for metabolic disease. ### Boosting Endogenous FGF21 (The Practical Approach) Since FGF21 analogs are not yet available, practitioners can leverage FGF21 biology through lifestyle interventions: - **Protein restriction days**: FGF21 is potently induced by protein restriction (not caloric restriction per se). Periodic low-protein days (1-2 days/week with <10% calories from protein) may boost FGF21. [Tier 2] - **Fasting/time-restricted eating**: Extended fasting (16+ hours) increases FGF21. This may be one mechanism behind intermittent fasting benefits. [Tier 2] - **Ketogenic diet**: Ketosis increases FGF21. The metabolic benefits of ketogenic diets may be partly FGF21-mediated. [Tier 2] - **Cold exposure**: Acute cold exposure increases FGF21 as part of thermogenic activation. [Tier 2] - **Exercise**: Intense exercise increases circulating FGF21. [Tier 2] - **Metformin**: Increases FGF21 levels (another possible mechanism of metformin's metabolic benefits). [Tier 2] ### Clinical Relevance for Peptide Practitioners - **NASH patients**: FGF21 pathway is the most promising emerging therapy for fatty liver disease. Awareness of efruxifermin and similar agents is important. - **Metabolic optimization**: Understanding FGF21 biology helps design lifestyle interventions (protein cycling, fasting, cold exposure) that activate this beneficial pathway. - **Longevity protocols**: FGF21 activation through lifestyle mirrors some of the longevity benefits seen in animal models. - **Sweet/alcohol cravings**: Patients with strong sweet cravings or alcohol preference may benefit from FGF21-boosting strategies. ### Safety Considerations - FGF21 analog side effects in trials: nausea, diarrhea, increased bone turnover markers - Bone health concern: FGF21 may promote bone loss through increased bone resorption. This needs monitoring in long-term use. - FGF21 is a stress-responsive hormone — chronically elevated levels may indicate metabolic dysfunction rather than optimal health

Evidence

• Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis.

  Loomba et al. (2026) — Clinical Gastroenterology and Hepatology — PMID: 41655805

  Secondary analysis of the pegozafermin randomized placebo-controlled trial found that large MRI-PDFF liver-fat reductions tracked with fibrosis improvement and MASH resolution, reinforcing biomarker-linked clinical activity for the FGF21 class.

  moderate

• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.

  Noureddin et al. (2025) — Lancet — PMID: 40818852

  FGF21 analog efruxifermin improved fibrosis and MASH outcomes over placebo across the HARMONY phase 2b program, supporting FGF21-pathway efficacy in biopsy-confirmed F2-F3 MASH.

  strong

• Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.

  Noureddin et al. (2025) — The New England Journal of Medicine — PMID: 40341827

  In compensated cirrhosis due to MASH, efruxifermin showed mixed histologic results at 36 weeks but remains important Tier 1 human evidence defining the limits and potential of FGF21 analog therapy in advanced disease.

  moderate

Research Summary

## FGF21 — Research Summary ### Tier 1 (Strong Clinical Evidence) - **Longevity in mice**: FGF21 transgenic overexpression extends lifespan ~40% (Zhang et al., 2012, eLife). Well-replicated. - **NASH clinical trials**: Efruxifermin Phase 2 showed dramatic liver fat reduction (up to 70%) and fibrosis improvement. Strong human efficacy signal. - **Metabolic biology**: FGF21 as metabolic regulator is well-characterized. Extensive basic science literature. - **Genetic associations**: GWAS data linking FGF21 variants to sweet preference, alcohol consumption, and metabolic traits. - **Fasting/protein restriction induction**: Well-documented FGF21 increase with fasting, protein restriction, and ketosis. ### Tier 2 (Moderate Evidence) - **Cardiovascular benefit**: Preclinical cardioprotection data. Clinical lipid improvements in human trials. - **Brown fat activation**: Thermogenesis stimulation well-characterized in animal models. Human brown fat activation less certain. - **Neuroprotection**: Emerging preclinical data. Human neurological studies limited. - **Bone concerns**: Clinical trial data showing increased bone turnover markers. Long-term bone safety unclear. ### Tier 3 (Emerging) - **Alcohol addiction**: FGF21 for reducing alcohol preference is an exciting emerging application. - **Longevity translation**: Whether FGF21's dramatic mouse longevity benefit translates to humans is unknown. ### Key Research Gaps - Efruxifermin Phase 3 results for NASH (pivotal trials ongoing) - Long-term bone safety of FGF21 analogs - Human longevity translation - Optimal lifestyle strategies for FGF21 activation